Navigation Links
Moffitt Cancer Center researchers find acidic pH microenvironments in tumors aid tumor cell survival
Date:9/5/2012

Researchers at Moffitt Cancer Center and colleagues at the University of South Florida and Wayne State University have discovered that tumor cell survival relies on adaptation to acidic conditions in the tumor microenvironment. Their research investigating the effects of acidity on breast and pancreatic cancer cell lines revealed the importance of autophagy in acidic microenvironments and suggests that a successful treatment strategy might be based on this autophagic dependence.

The study appears as the cover story for the Aug. 15 issue of Cancer Research, a publication of the American Association for Cancer Research.

"Cancer progression is a multistep process strongly influenced by the physical properties of the tumor microenvironment," said Robert J. Gillies, Ph.D., corresponding author of the study and chair of Moffitt's Department of Cancer Imaging and Metabolism. "Both low oxygen and high acidity can be cytotoxic. Our research suggests that adaptation to these stressful conditions involves autophagy allowing cancer cells to survive, proliferate and eventually metastasize to secondary sites."

According to the authors, not much is known about cell survival mechanisms under acidic conditions, but it has been demonstrated that acidosis can alter gene expression leading to cell types that are adapted for growth and survival in low pH conditions. Identifying low pH survival mechanisms would "give further insight into tumor progression and potentially introduce novel therapeutic strategies," researchers said.

In this study, the researchers tested cancer cell lines under acidic conditions to learn more about autophagy and cellular adaptation. They noted that normal cells in the acidic environment can respond to acidic stress by increasing cell death pathways, thus introducing the need for survival and adaptive mechanisms by cancer cells.

The researchers also noted that their experiments were carried out under atmospheric oxygen levels and they found that the cell's stress response could lead to chronic autophagy even when nutrients and oxygen were in adequate supply.

"We found that cells subjected to transient and chronic low pH growth conditions demonstrate elevated markers for autophagy and are dependent on this process for prolonged survival in acidic environments," explained Jonathan W. Wojtkowiak, lead author of the study and postdoctoral fellow at Moffitt. "A hallmark of cancer is the ability of cancer cells to evade apoptosis. Autophagy supports this by playing a tumor promoter and survival role under certain circumstances during different stages of tumorogenesis."

Their study demonstrated the importance of autophagy in low pH-adapted breast and pancreatic cancer cell lines and the dependence of these cells on autophagy for survival to acidic tumor microenvironment. According to the researchers, they identified a potential therapeutic strategy of using an autophagy inhibitor, one that does not affect cells under neutral conditions.


'/>"/>

Contact: Kim Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Review finds some evidence for chemo brain in breast cancer survivors, Moffitt Cancer Center says
2. Moffitt Cancer Center researchers and colleagues identify PHF20, a regulator of gene P53
3. Moffitt Cancer Center melanoma expert reviews unique adverse events with newly approved drug
4. Moffitt Cancer Center researchers validate molecular signature to predict radiation therapy benefit
5. Moffitt Cancer Center researchers discover how cancer cells hijack a mechanism to grow
6. Attitudes toward outdoor smoking ban at moffitt Cancer Center evaluated
7. Moffitt Cancer Center researcher & colleagues test new drug for patients with neuroendocrine tumors
8. Moffitt Cancer Center researchers find potential key to new treatment for mantle cell lymphoma
9. Moffitt Cancer Center study validates activity of rare genetic variant in glioma
10. Moffitt researchers find cutaneous human papillomavirus infection a risk factor for skin cancer
11. Moffitt Cancer Center researchers test drug combinations to prevent graft vs. host disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... , ... September 20, 2017 , ... “Monique”: is ... uncomfortable situations. “Monique” is the creation of published author, Colleen Crispi, has owned four ... then Crispi has been involved in real estate and cooking. , “The doctor’s ...
(Date:9/19/2017)... New York, NY (PRWEB) , ... September 19, ... ... communications firm, announced today the addition of strategic marketing leader, Denise Flannery, to ... as Strategic Marketing, Brand and Management Consultant, Denise will work with clients across ...
(Date:9/19/2017)... ... September 19, 2017 , ... Peter Chandonait, ... President’s Malaria Initiative (PMI) Africa Indoor Residual Spraying (AIRS) Project , has ... , The Innovation to Action Award, a USAID Catalyst Award, recognizes USAID staff ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... winners of the Entrepreneur Innovation Awards (EIA), held this past Thursday night at ... Connecticut-based companies and entrepreneurs, presented their innovative project ideas to a panel of ...
(Date:9/19/2017)... ... September 19, 2017 , ... The American Board ... to watch for the discomforts and hidden dangers of foot fungus, particularly in ... is at risk for developing fungal infections on the feet or toenails, the ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... Sept. 6, 2017  Medical professionals are ... skills while treating their patients. Medical simulations ... without involving patients. Simulation provides a safe ... carry out procedures, refine techniques and build ... of new technology, such as augmented reality, ...
(Date:9/6/2017)... NeuroRx, a clinical stage biopharma company developing the ... has been granted Fast Track status by the US Food ... HCl) followed by NRX-101 (D-cycloserine + lurasidone). The company will ... sequential therapy targeting patients who are admitted to Emergency Departments ... ...
(Date:9/5/2017)... -- Sapheneia and Scannerside received FDA 510(k) clearance to ... third-party Vendor neutral CT product that makes it affordable ... current MITA standards. ... specifically designed to provide CT operators, prior to a ... a predefined threshold. Scannerside Dose Check is intended to ...
Breaking Medicine Technology: